Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11985870 | 0.81 | HSP90AA1 (0.42) | HSD17B10KDM4EHPGD | |
| SCHEMBL25951828 | 0.79 | KDM4E (0.32) | HSD17B10KDM4EGAAHPGD | |
| SCHEMBL16080761 | 0.77 | KDM4E (0.39) | HSD17B10KDM4EGAAHPGDTDP1 | |
| SCHEMBL11937170 | 0.76 | HSD17B10 (0.37) | HSD17B10KDM4EHPGD | |
| SCHEMBL3176326 | 0.76 | HSD17B10 (0.34) | HSD17B10KDM4EGAAHPGD | |
| SCHEMBL20457067 | 0.74 | HRH4 (0.35) | HSD17B10KDM4EGAAHPGD | |
| SCHEMBL11985866 | 0.72 | TDP1 (0.35) | TDP1 | |
| SCHEMBL11985869 | 0.72 | CYP1A2 (0.37) | KDM4EGAATDP1 | |
| SCHEMBL8008974 | 0.71 | TDP1 (0.36) | KDM4ETDP1 | |
| SCHEMBL26860474 | 0.71 | TDP1 (0.32) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | HSD17B10 2328/4885KDM4E 3629/4885GAA 2175/4885 |
| US-11708351-B2 | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | CFD, TFPI, CFH | HSD17B10 1063/4885KDM4E 3553/4885GAA 1549/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | HSD17B10 1063/4885KDM4E 3553/4885GAA 1549/4885 |
| US-11814391-B2 | Macrocyclic compounds for the treatment of medical disorders | CFD, TFPI, CFH | HSD17B10 2634/4885KDM4E 4570/4885GAA 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.